Actinium Pharmaceuticals (ATNM) Non-Current Debt (2010 - 2014)

Actinium Pharmaceuticals (ATNM) posted quarterly Non-Current Debt of $54970.0 for Q2 2014, down 41.82% quarter-over-quarter from $94481.0 in Q1 2014.

Actinium Pharmaceuticals (ATNM) Non-Current Debt (2010 - 2014) Analysis & Trends

Actinium Pharmaceuticals (ATNM) has reported Non-Current Debt for 5 consecutive years, with $54970.0 the latest figure, recorded in Q2 2014.

In Q2 2014, Non-Current Debt changed N/A year-over-year to $54970.0; the TTM figure through Jun 2014 stood at $54970.0 (changed N/A YoY), while the FY2013 annual figure was $157825.0, changed N/A from the prior year.
Non-Current Debt fell to $54970.0 in Q2 2014 per ATNM's latest filing, from $94481.0 in the prior quarter.
Across five years, Non-Current Debt topped out at $157825.0 in Q4 2013 and bottomed at $54970.0 in Q2 2014.
Historically, Non-Current Debt has averaged $79055.1 across 5 years, with a median of $67716.5 in 2012.
On a YoY basis, Non-Current Debt climbed as much as 0.92% in 2011 and fell as far as 0.92% in 2011.
Actinium Pharmaceuticals' Non-Current Debt stood at $58707.0 in 2010, then fell by 0.92% to $58168.0 in 2011, then climbed by 25.25% to $72857.0 in 2012, then soared by 116.62% to $157825.0 in 2013, then plunged by 65.17% to $54970.0 in 2014.
Business Quant data shows ATNM's Non-Current Debt at $54970.0 in Q2 2014, $94481.0 in Q1 2014, and $157825.0 in Q4 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	882.16 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	360.97 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	8.96 Bn
10	Actinium Pharmaceuticals	35.01 Mn	35.01 Mn	-	-

Download Data